Table 2.
Clinical Outcomes of the Frontline Cohort1
| All (n=60) | Non-tsAML (n=43) | tsAML (n=17) | IDH1mut (n=37) | IDH2mut (n=23) | |
|---|---|---|---|---|---|
| 2-year OS | 69 (57 – 83) | 84 (73 – 97) | 34 (16 – 71) | 72 (57 – 90) | 67 (49 – 91) |
| 2-year EFS | 67 (56 – 81) | 79 (66 – 93) | 34 (21 – 73) | 72 (58 – 88) | 62 (44 – 87) |
| 2-year CIR2 | 24 (6 – 39) | 20 (0 – 36) | 38 (0 – 65) | 26 (0 – 46) | 22 (0 – 43) |
| 30-day mortality | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 60-day mortality | 1 (2) | 0 (0) | 1 (6) | 0 (0) | 1 (4) |
| CRc3 | 55 (92) | 42 (98) | 13 (71) | 32 (86) | 23 (100) |
| ORR | 57 (95) | 43 (100) | 14 (82) | 34 (92) | 23 (100) |
| MRD negativity | 45 (87) | 35 (88) | 10 (83) | 25 (81) | 20 (95) |
1
% (95% CI); n(%)
2
Censored at SCT
3
Within 5 cycles of treatment
4
By multiparameter flow cytometry at best response, sensitivity 10−4 (excluding inadequate samples or unknown)